Feb 1 |
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
|
Jan 31 |
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
|
Jan 31 |
Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward
|
Jan 9 |
Are Investors Undervaluing Cabaletta Bio, Inc. (NASDAQ:CABA) By 47%?
|
Jan 8 |
Cabaletta Bio gains on FDA fast-track tags for lead asset
|
Jan 8 |
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
|
Jan 2 |
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
Dec 19 |
Cabaletta Bio Stock (NASDAQ:CABA): Analysts Expect More Gains Despite Massive Rally
|
Dec 11 |
Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology
|
Dec 10 |
Buy Cabaletta Bio's Promising SLE Treatment
|